TABLE 3.
Pharmacokinetic parameters of lenvatinib in adult and juvenile rats (7.0 mg/kg, means ± SD., n = 5–6).
| Analysis mode | Adult rat | Juvenile rat |
|---|---|---|
| Two compartment model | ||
| T1/2α(h) | 216.58 ± 310.32 | a 104.35 ± 224.20 |
| T1/2β(h) | 45,376.84 ± 52,704.20 | 25,495.5 ± 44,224.25 |
| T1/2Ka(h) | 191.35 ± 299.97 | **2.45 ± 3.38 |
| V1/F (L·kg-1) | 10.14 ± 12.15 | a 18,549.10 ± 41,446.83 |
| CL/F (L·h-1·kg-1) | 2.25 ± 0.68 | 2.71 ± 1.95 |
| AUC(0-∞) (μg·mL-1·h) | 3.35 ± 0.96 | 4.15 ± 3.10 |
| R 2 | 0.83 ± 0.14 | 0.83 ± 0.10 |
| Statistical moments | ||
| T1/2(h) | 13.80 ± 4.28 | a 80.79 ± 105.80 |
| V/F (L·kg-1) | 35.82 ± 12.18 | a 109.78 ± 95.17 |
| CL/F (L·h-1·kg-1) | 1.82 ± 0.34 | a 1.28 ± 0.35 |
| AUC(0-∞) (μg·mL-1·h) | 3.97 ± 0.73 | 5.95 ± 2.27 |
| AUMC(0-∞) | 78.98 ± 37.29 | a 985.10 ± 1,445.02 |
| MRT(0-∞) (h) | 19.64 ± 7.64 | **126.38 ± 130.18 |
| Cmax (μg·mL-1) | 0.32 ± 0.08 | 0.28 ± 0.04 |
| Tmax(h) | 3.5 ± 0.73 | a 2.0 ± 0.00 |
T1/2, half-life; V/F, apparent volume of distribution corrected for extravascular bioavailability; CL/F, clearance corrected for extravascular bioavailability; AUC(0–∞), area under the 0–∞ drug-time curve; AUMC(0-∞), area under the 0-∞ first-order moment curve; MRT (0-∞), 0–∞ mean retention time; Cmax, peak concentration; Tmax: time to peak concentration.
a
Indicates statistically significant difference in lenvatinib compared to juvenile rats using independent sample t-test i.e., *indicates p < 0.05,**indicates p < 0.01.